| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:2479.)
© 2005 American Heart Association, Inc.
Research Reports |
From the Yale Neurovascular Surgery Program (B.G., A.K.O., K.L.P., M.G.), Department of Neurosurgery, Yale University School of Medicine, New Haven, Conn; Acibadem Hospital (A.S.), Istanbul, Turkey; Marmara University School of Medicine (M.O.), Istanbul, Turkey.
Correspondence to Murat Gunel, Yale Neurovascular Surgery Program, Department of Neurosurgery, Yale University School of Medicine, 333 Cedar St, TMP4, New Haven, CT, 06510. E-mail murat.gunel{at}yale.edu
| Abstract |
|---|
|
|
|---|
Methods We have identified and ascertained over 200 families with CCM. Among these, 1 unique family was found to have members affected by both disorders. We have performed mutational analysis in all 3 CCM genes, KRIT1, Malcavernin, and PDCD10, to identify the causative gene in the family.
Results Mutational analysis revealed a frameshift mutation affecting exon 19 of the CCM1 gene (KRIT1) in members with CCM, whereas no such mutation was observed in the member with CVM.
Conclusions These findings support the hypothesis that CVM and CCM are 2 distinct entities with different pathogenetic mechanisms. This data further supports the hypothesis that CVM has a distinct biology and clinical behavior when compared to CCM. CVM is a benign developmental anomaly and should be managed separately from CCM.
Key Words: cerebral venous malformation cerebral cavernous malformation KRIT1 molecular genetics
| Introduction |
|---|
|
|
|---|
Controversy exists regarding the origin and pathogenesis of cerebral venous angiomas. CVMs are most often solitary but may present with multiple lesions; specifically, as high as 25% of CVMs co-occur with cerebral cavernous malformations (CCM), leading many authors to suggest that these lesions share a common origin and pathogenetic mechanism with CCMs.3 CCM is characterized by abnormally dilated sinusoidal channels lined with a single layer of endothelial cells without any other vessel wall elements.4 The most common symptoms associated with the disease are seizures and neurological deficits that may result from focal hemorrhages.5 CCMs occur both in a sporadic and inherited form.
| Subjects and Methods |
|---|
|
|
|---|
|
To test this hypothesis, we searched for mutations in the known CCM genes, KRIT1 (OMIM*604214) on 7q11,6 Malcavernin (MGC4607; OMIM*607929) on 7p22,7 and Programmed Cell Death 10 (PDCD10; OMIM*609118) on 3q.8 Patient DNA was obtained from blood samples using standard chloroform-phenol extraction method, and the three genes were directly sequenced via polymerase chain reaction. Results were subsequently analyzed using the Sequencher program version 4.2 (Gene Codes Corp).
| Results |
|---|
|
|
|---|
| Discussion |
|---|
|
|
|---|
Our results thus show that mutations in the KRIT1 gene are not necessary for CVM formation. Given the fact that carriers of KRIT1 mutations develop CCM lesions that are detectable by MRI in only 62% of cases,11 mutations in CCM genes are necessary but not sufficient for the development of CCM. Other factors, most likely a second somatic mutation, is needed to form CCM lesions.12 Recent data on CCM transgenic mice also support this hypothesis, showing that only CCM1 (+/), p53 (/) double transgenic mice develop CCM, most likely attributed to accelerated somatic mutation rate, whereas CCM1 (+/) single transgenic mice do not.10 In this article, we provide evidence that supports the hypothesis that CVM and CCM are two distinct entities with different pathogenetic mechanisms underlying these disorders. This data provides further support to the hypothesis that CVMs and CCMs have distinct biology and clinical behavior and that they should be managed accordingly.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received April 22, 2005; revision received June 6, 2005; accepted June 30, 2005.
| References |
|---|
|
|
|---|
2. Senegor M, Dohrmann GJ, Wollmann RL. Venous angiomas of the posterior fossa should be considered as anomalous venous drainage. Surg Neurol. 1983; 19: 2632.[CrossRef][Medline] [Order article via Infotrieve]
3. Abe T, Singer RJ, Marks MP, Norbash AM, Crowley RS, Steinberg GK. Coexistence of occult vascular malformations and developmental venous anomalies in the central nervous system: MR evaluation. Am J Neuroradiol. 1998; 19: 5157.[Abstract]
4. Russell DR. Pathology of Tumors of the Nervous System. Baltimore, MD: Williams and Wilkins. 1989.
5. Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg. 1991; 75: 709714.[Medline] [Order article via Infotrieve]
6. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, Cecillon M, Marechal E, Joutel A, Bach JF, Tournier-Lasserve E. Truncating mutations in CCM1, encoding krit1, cause hereditary cavernous angiomas. Nature Genet. 1999; 23: 189193.[CrossRef][Medline] [Order article via Infotrieve]
7. Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A, Benabid AL, Comoy J, Frerebeau P, Gilbert B, Houtteville JP, Jan M, Lapierre F, Loiseau H, Menei P, Mercier P, Moreau JJ, Nivelon-Chevallier A, Parker F, Redondo AM, Scarabin JM, Tremoulet M, Zerah M, Maciazek J, Tournier-Lasserve E; Societe Francaise de Neurochirurgie. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet. 2004; 74: 326337.[CrossRef][Medline] [Order article via Infotrieve]
8. Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P, Echenne B, Ibrahim R, Irthum B, Jacquet G, Lonjon M, Moreau JJ, Neau JP, Parker F, Tremoulet M, Tournier-Lasserve E. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet. 2005; 76: 4251.[CrossRef][Medline] [Order article via Infotrieve]
9. Guzeloglu-Kayisli O, Amankulor NM, Voorhees J, Luleci G, Lifton RP, Gunel M. Krit1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery. 2004; 54: 943949; discussion 949.
10. Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. Loss of p53 sensitizes mice with a mutation in CCM1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol. 2004; 165: 15091518.
11. Denier C, Labauge P, Brunereau L, Cave-Riant F, Marchelli F, Arnoult M, Cecillon M, Maciazek J, Joutel A, Tournier-Lasserve E; Societe Francaise de Neurochirurgie; Societe de Neurochirurgie de Langue Francaise. Clinical features of cerebral cavernous malformations patients with KRIT1 mutations. Ann Neurol. 2004; 55: 213220.[CrossRef][Medline] [Order article via Infotrieve]
12. Gault J, Shenkar R, Recksiek P, Awad IA. Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005; 36: 872874.
Related Article:
Stroke 2005 36: 2339.
This article has been cited by other articles:
![]() |
C. Shi, R. Shenkar, H. Du, E. Duckworth, H. Raja, H. H. Batjer, and I. A. Awad Immune Response in Human Cerebral Cavernous Malformations Stroke, May 1, 2009; 40(5): 1659 - 1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-H. Tan, H. N Baris, P. E Burrows, C. D Robson, A. I Alomari, J. B Mulliken, S. J Fishman, and M. B Irons The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management J. Med. Genet., September 1, 2007; 44(9): 594 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Stahl and U. Felbor Controversial Molecular Classification of Human Cerebrovascular Malformations Stroke, September 1, 2006; 37(9): 2214 - 2214. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |